BACKGROUND: Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. METHODS: As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18-39 years. RESULTS: Among 4,121 CIN2+ cases reported during 2008-2009 in 18- to 39-year-old women 3058 (74.2%) were tested; 96% were HPV DNA positive. HPV 16 was most common (49.1%), followed by HPV 31 (10.4%) and HPV 52 (9.7%). HPV 18 prevalence was 5.5% overall. Proportion of CIN2+ cases associated with HPV 16/18 was highest (56.3%) in 25- to 29-year-old women. HPV 16/18-associated lesions were less common in non-Hispanic blacks (41.9%) and Hispanics (46.3%) compared with non-Hispanic whites (59.1%) (P < .0001); the difference remained significant when adjusted for covariates. Compared to non-Hispanic whites, HPV 35 and 58 were significantly more common in non-Hispanic blacks (14.5% vs 4.2%; 12.3% vs 3.4%) and HPV 45 was higher in Hispanics (3.7% vs 1.5%). CONCLUSIONS: Age and racial/ethnic differences in HPV type distribution may have implications for vaccine impact and should be considered in monitoring trends.
BACKGROUND: Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. METHODS: As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18-39 years. RESULTS: Among 4,121 CIN2+ cases reported during 2008-2009 in 18- to 39-year-old women 3058 (74.2%) were tested; 96% were HPV DNA positive. HPV 16 was most common (49.1%), followed by HPV 31 (10.4%) and HPV 52 (9.7%). HPV 18 prevalence was 5.5% overall. Proportion of CIN2+ cases associated with HPV 16/18 was highest (56.3%) in 25- to 29-year-old women. HPV 16/18-associated lesions were less common in non-Hispanic blacks (41.9%) and Hispanics (46.3%) compared with non-Hispanic whites (59.1%) (P < .0001); the difference remained significant when adjusted for covariates. Compared to non-Hispanic whites, HPV 35 and 58 were significantly more common in non-Hispanic blacks (14.5% vs 4.2%; 12.3% vs 3.4%) and HPV 45 was higher in Hispanics (3.7% vs 1.5%). CONCLUSIONS: Age and racial/ethnic differences in HPV type distribution may have implications for vaccine impact and should be considered in monitoring trends.
Authors: Ni Li; Silvia Franceschi; Rebecca Howell-Jones; Peter J F Snijders; Gary M Clifford Journal: Int J Cancer Date: 2011-02-15 Impact factor: 7.396
Authors: Mark Schiffman; Andrew G Glass; Nicolas Wentzensen; Brenda B Rush; Philip E Castle; David R Scott; Julie Buckland; Mark E Sherman; Greg Rydzak; Peter Kirk; Attila T Lorincz; Sholom Wacholder; Robert D Burk Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-05-20 Impact factor: 4.254
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Herschel W Lawson; Harrell Chesson; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2007-03-23
Authors: François Coutlée; Samuel Ratnam; Agnihotram V Ramanakumar; Ralph R Insinga; James Bentley; Nicholas Escott; Prafull Ghatage; Anita Koushik; Alex Ferenczy; Eduardo L Franco Journal: J Med Virol Date: 2011-06 Impact factor: 2.327
Authors: Cosette M Wheeler; William C Hunt; Nancy E Joste; Charles R Key; Wim G V Quint; Philip E Castle Journal: J Natl Cancer Inst Date: 2009-03-24 Impact factor: 13.506
Authors: Philip E Castle; Ana Cecilia Rodríguez; Robert D Burk; Rolando Herrero; Sholom Wacholder; Mario Alfaro; Jorge Morales; Diego Guillen; Mark E Sherman; Diane Solomon; Mark Schiffman Journal: BMJ Date: 2009-07-28
Authors: Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-02 Impact factor: 4.254
Authors: Monica Trevino; Susan Padalecki; Anand Karnad; Alberto Parra; Steve Weitman; Melissa Nashawati; Brad H Pollock; Amelie Ramirez; Ian M Thompson Journal: J Community Med Health Educ Date: 2013-09-01
Authors: Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden Journal: Clin Vaccine Immunol Date: 2015-05-13
Authors: M J Binnicker; B S Pritt; B J Duresko; M J Espy; T E Grys; M A Zarka; S E Kerr; M R Henry Journal: J Clin Microbiol Date: 2014-08-13 Impact factor: 5.948
Authors: J R Montealegre; E C Peckham-Gregory; D Marquez-Do; L Dillon; M Guillaud; K Adler-Storthz; M Follen; M E Scheurer Journal: Gynecol Oncol Date: 2017-12-21 Impact factor: 5.482
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Jane R Montealegre; Indu Varier; Christina G Bracamontes; Laura M Dillon; Martial Guillaud; Andrew G Sikora; Michele Follen; Karen Adler-Storthz; Michael E Scheurer Journal: Ethn Health Date: 2017-09-04 Impact factor: 2.772
Authors: Dana Whittemore; Lili Ding; Lea E Widdice; Darron A Brown; David I Bernstein; Eduardo L Franco; Jessica A Kahn Journal: J Womens Health (Larchmt) Date: 2016-10-18 Impact factor: 2.681